# NRG-LU008 (NCT05624996)

> Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: none (the trial tests a strategy, not a drug)
- Indication: locally advanced inoperable non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05624996
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: NRG Oncology
- Conditions: Locally Advanced Lung Non-Small Cell Carcinoma; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8
- Interventions: Carboplatin; Cisplatin; Computed Tomography; Durvalumab; Etoposide; Image Guided Radiation Therapy; Nab-paclitaxel; Osimertinib; Paclitaxel; Pemetrexed; Positron Emission Tomography; Questionnaire Administration; Stereotactic Body Radiation Therapy
- Enrollment: 474
- Primary outcome: Overall survival (OS)
- Primary outcome: Progression-free survival (PFS)

## Indexed commentary on NRG-LU008 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 11 posts on X
- 2 YouTube videos
- 2 podcast episodes

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nrg-lu008-nct05624996

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05624996", "email": "<work email>"}; the inbox owner confirms by the emailed link.
